{"product_id":"rnxt-vrio-analysis","title":"RenovoRx, Inc. (RNXT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking sustainable competitive advantage for RenovoRx, Inc. (RNXT) hinges on a critical assessment: are its core resources truly Valuable, Rare, Inimitable, and Organized? This VRIO analysis distills the answer, providing a sharp summary of the firm's strategic position, as detailed in \u0026amp;O4\u0026amp;. Read on to uncover the definitive verdict on whether RenovoRx, Inc. (RNXT) possesses the foundation for long-term market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 1. Patented Trans-Arterial Micro-Perfusion (TAMP™) Platform and IP Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of RenovoRx, the TAMP™ platform, and trying to figure out if that technology moat is real enough to hold up against future competition. Honestly, the IP looks solid, but the real test is execution, which we are starting to see play out in the market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Targeted Delivery is Key\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe TAMP™ platform is valuable because it solves a major problem in treating solid tumors like pancreatic cancer: getting high drug concentrations right at the source while sparing the rest of the body. For Locally Advanced Pancreatic Cancer (LAPC), where the standard of care (systemic IV gemcitabine and nab-paclitaxel) often struggles due to poor tumor blood supply and causes debilitating side effects, this targeted approach is a game-changer. The potential for increased efficacy and reduced systemic toxicity is what drives physician interest and justifies the device’s use.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: A Unique Delivery Mechanism\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific mechanism of the TAMP™ platform, enabled by the FDA-cleared RenovoCath® device, is rare. The company backs this uniqueness with a substantial intellectual property shield. As of Q1 2025, RenovoRx held a portfolio of 19 patents globally. This isn't just one patent; it’s a thicket designed to cover the method of delivery itself.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Legal Barriers are High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImitation is difficult here, primarily due to the legal barriers. The initial analysis noted a significant moat: 9 U.S. patents issued and 7 U.S. patents pending as of Q1 2025. This patent thicket makes direct replication a costly, time-consuming legal gamble for any competitor. Plus, the Orphan Drug Designation for pancreatic cancer grants seven years of market exclusivity upon New Drug Application approval, adding a regulatory layer to the protection.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Commercial Traction Confirms Use\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes, RenovoRx is organized to exploit this asset. They are actively driving both commercial sales of RenovoCath and the pivotal Phase III TIGeR-PaC trial. Here’s the quick math on their commercial ramp-up: Q1 2025 saw $200,000 in revenue, which grew to $266,000 in Q3 2025, pushing year-to-date revenue to approximately $900,000 by September 30, 2025. They had $10.0 million in cash at that date, which management believes funds commercial scale-up and completion of TIGeR-PaC enrollment in early 2026. What this estimate hides is the need to scale sales effectively from their current base of about 14 cancer centers.\u003c\/p\u003e\n\n\u003cp\u003eThe TAMP platform’s competitive standing can be summarized like this:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnables targeted delivery, addressing poor tumor blood supply in LAPC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUnique delivery mechanism; 19 global patents issued as of Q1 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eCostly\/Difficult\u003c\/td\u003e\n\u003ctd\u003eProtected by 9 U.S. patents issued and 7 pending as of Q1 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eGenerating revenue ($900,000 YTD 2025) and advancing Phase III trial enrollment completion expected early 2026.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eStrong, legally protected IP combined with early commercial execution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe platform’s current advantage is sustained because the legal protection is robust, and the company is successfully translating the technology into revenue. Still, if onboarding new centers takes longer than expected, that cash runway could tighten before meaningful revenue growth kicks in.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTargeted delivery reduces systemic toxicity.\u003c\/li\u003e\n\u003cli\u003eIP portfolio includes 9 issued U.S. patents.\u003c\/li\u003e\n\u003cli\u003eCommercial revenue reached $900,000 YTD 2025.\u003c\/li\u003e\n\u003cli\u003eTrial enrollment completion targeted for early 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: update the 13-week cash flow projection to reflect Q3 SG\u0026amp;A burn of $1.7 million for the quarter.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 2. FDA-Cleared RenovoCath® Drug-Delivery Device (Standalone)\n\u003c\/h2\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe standalone device provides immediate, revenue-generating capability.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eAmount\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eYear-to-Date Revenue (Through Q3 2025)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$900,000\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$266,000\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eOther local delivery devices exist, but RenovoCath’s specific FDA clearance for its intended use is a key differentiator.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe device itself can be reverse-engineered, but the regulatory clearance is not easily replicated quickly.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company has successfully launched commercialization efforts, generating approximately \u003cstrong\u003e$900,000\u003c\/strong\u003e in year-to-date revenue through Q3 2025.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eApproved cancer centers as of November 7, 2025: \u003cstrong\u003e14\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eApproved cancer centers at the start of 2025: \u003cstrong\u003eFive\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFinancial Metric (As of Period End)\u003c\/td\u003e\n    \u003ctd\u003eQ2 2025 (June 30, 2025)\u003c\/td\u003e\n    \u003ctd\u003eQ3 2025 (September 30, 2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$12.3 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$10.0 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNet Loss for the Quarter\u003c\/td\u003e\n    \u003ctd\u003e$2.9 million\u003c\/td\u003e\n    \u003ctd\u003e$2.9 million\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. While currently valuable, sustained advantage depends on market penetration speed before competitors respond.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 3. Orphan Drug Designation for IAG Combination Product\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a potential \u003cstrong\u003e7 years\u003c\/strong\u003e of market exclusivity upon New Drug Application approval for pancreatic and bile duct cancer, securing future monopoly profits.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. This designation is granted selectively by the FDA for rare diseases, defined as affecting fewer than \u003cstrong\u003e200,000\u003c\/strong\u003e people in the U.S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Sustained. Regulatory designations are government-granted and cannot be imitated by competitors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company is actively advancing the Phase III TIGeR-PaC trial, which is the pathway to realizing this exclusivity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Regulatory exclusivity is a powerful, non-replicable asset.\u003c\/p\u003e\n\n\u003cp\u003eThe pathway to realizing the value of the Orphan Drug Designation is intrinsically linked to the progression of the pivotal Phase III TIGeR-PaC trial:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFeature\u003c\/th\u003e\n\u003cth\u003eValue\/Term\u003c\/th\u003e\n\u003cth\u003eStatus\/Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Exclusivity Period\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpon NDA approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Indications\u003c\/td\u003e\n\u003ctd\u003ePancreatic Cancer, Bile Duct Cancer\u003c\/td\u003e\n\u003ctd\u003eODD granted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTIGeR-PaC Final Analysis Patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e114\u003c\/strong\u003e randomized patients\u003c\/td\u003e\n\u003ctd\u003eRequired for final analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTIGeR-PaC Final Analysis Events\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e86\u003c\/strong\u003e events (deaths)\u003c\/td\u003e\n\u003ctd\u003eRequired for final analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond Interim Analysis Trigger\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e52\u003c\/strong\u003e events (deaths)\u003c\/td\u003e\n\u003ctd\u003eTriggered in Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare Disease Threshold (US)\u003c\/td\u003e\n\u003ctd\u003eFewer than \u003cstrong\u003e200,000\u003c\/strong\u003e people\u003c\/td\u003e\n\u003ctd\u003eDefinition of rare disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe trial progress as of recent reports includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of August 2025, the Independent Data Monitoring Committee recommended \u003cstrong\u003econtinuation\u003c\/strong\u003e of the trial after reviewing the second interim analysis based on the \u003cstrong\u003e52nd\u003c\/strong\u003e death.\u003c\/li\u003e\n\u003cli\u003eAs of March 28, 2025, \u003cstrong\u003e90\u003c\/strong\u003e patients had been randomized with \u003cstrong\u003e50\u003c\/strong\u003e events recorded.\u003c\/li\u003e\n\u003cli\u003eAs of August 2025, \u003cstrong\u003e95\u003c\/strong\u003e patients were enrolled in the TIGeR-PaC trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe IAG combination product is being evaluated against the standard-of-care, which involves combination regimens based on gemcitabine.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 4. Momentum in Pivotal Phase III TIGeR-PaC Clinical Trial\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates the potential to validate the drug-device combination (IAG) for a high-unmet-need indication (LAPC), which is the primary value driver.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies run Phase III trials, but positive DMC recommendations are rare achievements.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors cannot replicate the trial's specific patient data or the DMC’s positive recommendation to continue.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company is focused on completing enrollment in early 2026, showing clear project management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage is sustained only until final data is released; the outcome dictates the long-term value.\u003c\/p\u003e\n\u003cp\u003eThe momentum is quantified by the progression toward the final analysis and the recent positive Data Monitoring Committee (DMC) review.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Metric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eStatus\/Date Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Required Randomized Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e114\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProtocol Specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Required Events (Deaths) for Final Analysis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProtocol Specified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Randomized (as of August 12, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e95\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Update\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents Occurred (as of August 12, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Update\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSecond Interim Analysis Trigger\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e52nd\u003c\/strong\u003e Death\u003c\/td\u003e\n\u003ctd\u003eTriggered in Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMC Recommendation (2nd Analysis)\u003c\/td\u003e\n\u003ctd\u003eContinue Study\u003c\/td\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Completion Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEarly 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinal Data Anticipated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational focus is supported by dual-tracking commercial growth and clinical progress:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 RenovoCath Revenue: approximately $\u003cstrong\u003e200,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 RenovoCath Revenue: over $\u003cstrong\u003e400,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eYear-to-Date (Q3 2025) Revenue: approximately $\u003cstrong\u003e900,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents as of September 30, 2025: $\u003cstrong\u003e10.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInitial Total Addressable Market (TAM) for RenovoCath: estimated $\u003cstrong\u003e400 million\u003c\/strong\u003e peak annual U.S. sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey milestones related to the DMC review and enrollment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe first interim analysis was completed in March 2023, with the DMC recommending continuation.\u003c\/li\u003e\n\u003cli\u003eThe second pre-planned interim analysis was triggered by the \u003cstrong\u003e52nd\u003c\/strong\u003e death in the second quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eAs of March 28, 2025, \u003cstrong\u003e90\u003c\/strong\u003e patients had been randomized and \u003cstrong\u003e50\u003c\/strong\u003e events had occurred.\u003c\/li\u003e\n\u003cli\u003eThe DMC recommended to continue the trial following the second interim analysis.\u003c\/li\u003e\n\u003cli\u003eThe company elected to defer publishing the second interim data to preserve trial integrity for the FDA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 5. Early-Stage Commercialization Engine and Revenue Stream\n\u003c\/h2\u003e\n\u003cp\u003e\nThe early-stage commercialization engine is generating initial revenue streams from the RenovoCath device sales.\n\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\nGenerates cash flow to offset burn rate and provides real-world feedback on device use and sales cycles.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$266,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-to-Date Revenue (9 months ended 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$900,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\nLow. Other medical device companies have sales teams.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpense Category (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, General, and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\nLow. Competitors can hire sales staff and start selling.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHiring of Philip Stocton as Senior Director of Sales \u0026amp; Market Development in August 2025.\u003c\/li\u003e\n\u003cli\u003eTwo regional sales managers hired to build the foundation for sustained growth.\u003c\/li\u003e\n\u003cli\u003eCommercialization efforts handled by limited staff initially.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\nYes. The company has established a commercial strategy, evidenced by \u003cstrong\u003e$266,000\u003c\/strong\u003e in Q3 2025 revenue alone.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Milestone\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved Cancer Centers (as of Nov 7, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved Cancer Centers (start of 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\nTemporary. The first-mover advantage in this specific niche is fleeting without rapid scaling.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Opportunity Estimate\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Initial TAM for RenovoCath (Peak Annual U.S. Sales)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$400 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Estimate (based on current plan)\u003c\/td\u003e\n\u003ctd\u003eInto the \u003cstrong\u003emiddle of 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 6. Growing Network of Adopting Cancer Centers\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates institutional familiarity and physician advocacy for the TAMP platform, which is crucial for long-term standard-of-care adoption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The quality of centers matters more than the count; including NCI-designated centers is key.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building trust and securing purchase agreements with top centers takes time and relationships.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The base grew from \u003cstrong\u003e5\u003c\/strong\u003e centers at the start of \u003cstrong\u003e2025\u003c\/strong\u003e to \u003cstrong\u003e14\u003c\/strong\u003e approved centers by \u003cstrong\u003eQ3 2025\u003c\/strong\u003e, with repeat orders noted.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Relationships are sticky, but new competitors can target these centers with superior data or pricing.\u003c\/p\u003e\n\n\u003cp\u003eKey adoption and financial metrics supporting the network growth:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e centers were approved to purchase RenovoCath at the start of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBy the \u003cstrong\u003eQ3 2025\u003c\/strong\u003e earnings call, \u003cstrong\u003e14\u003c\/strong\u003e cancer centers were approved to purchase RenovoCath.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e of the approved centers had used the device in patients and made repeat orders as of the \u003cstrong\u003eQ3 2025\u003c\/strong\u003e update.\u003c\/li\u003e\n\u003cli\u003eThe sales pipeline included product quotes delivered to \u003cstrong\u003e10\u003c\/strong\u003e additional leading centers, totaling \u003cstrong\u003e24\u003c\/strong\u003e centers that formally requested quotes as of the \u003cstrong\u003eQ3 2025\u003c\/strong\u003e call.\u003c\/li\u003e\n\u003cli\u003eThe Phase III TIGeR-PaC trial involved approximately \u003cstrong\u003e18\u003c\/strong\u003e cancer centers that used RenovoCath and are potential future customers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eTime Period\/Date\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved Purchase Centers\u003c\/td\u003e\n\u003ctd\u003eStart of 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved Purchase Centers\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (as of Sept 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e14\u003c\/strong\u003e centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Centers with Repeat Orders\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5\u003c\/strong\u003e centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenovoCath Revenue\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$200,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenovoCath Revenue\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e$400,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenovoCath Revenue\u003c\/td\u003e\n\u003ctd\u003eYear-to-Date (through Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$900,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eMarch 31, 2025 (Q1 End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025 (Q3 End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Initial TAM (Standalone Device)\u003c\/td\u003e\n\u003ctd\u003ePeak Annual U.S. Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$400 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 7. Lean Operating Structure with Sufficient Cash Runway\u003c\/h2\u003e\n\u003cp\u003eThe assessment of the lean operating structure and cash runway is critical for evaluating the company's near-term viability and strategic flexibility.\u003c\/p\u003e\n\u003ch5\u003e\u003ch\u003eValue: Extends the time before needing dilutive financing, allowing management to hit critical clinical milestones.\u003c\/h\u003e\u003c\/h5\u003e\n\u003cp\u003eThe current cash position is positioned to fund operations through the anticipated completion of TIGeR-PaC enrollment in \u003cstrong\u003eearly 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch5\u003e\u003ch\u003eRarity: Low. Many smaller firms manage cash tightly.\u003c\/h\u003e\u003c\/h5\u003e\n\u003cp\u003eThe management of capital structure and expense control is common among smaller, clinical-stage life sciences entities.\u003c\/p\u003e\n\u003ch5\u003e\u003ch\u003eImitability: Low. This is a function of capital structure and expense control.\u003c\/h\u003e\u003c\/h5\u003e\n\u003cp\u003eThe duration of the runway is directly tied to the capital raised and the ongoing operational expenditure rate.\u003c\/p\u003e\n\u003ch5\u003e\u003ch\u003eOrganization: Yes. Management believes the $10.0 million cash position as of September 30, 2025, is sufficient to fund commercial scale-up and TIGeR-PaC enrollment completion.\u003c\/h\u003e\u003c\/h5\u003e\n\u003cp\u003eManagement has explicitly stated confidence in the current cash level to achieve key milestones under the existing operating plan.\u003c\/p\u003e\n\u003cp\u003eThe following table details the financial position and operating expenses as of the third quarter ended \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (As of 09\/30\/2025 or Q3 2025)\u003c\/th\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, General, and Administrative Expenses (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal RenovoCath Revenue (First Nine Months 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$900,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Shares Outstanding (As of 09\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e36.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eShares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe lean structure is supported by the following operational metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTIGeR-PaC Enrollment Completion Target: \u003cstrong\u003eEarly 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Runway Projection: Sufficient to fund activities into \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eApproved Purchasing Cancer Centers: \u003cstrong\u003e14\u003c\/strong\u003e centers.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e$2.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003e\u003ch\u003eCompetitive Advantage: Temporary. The runway is finite; it buys time but doesn't create market share.\u003c\/h\u003e\u003c\/h5\u003e\n\u003cp\u003eThe advantage is derived from the time purchased to reach the next value inflection point, such as TIGeR-PaC data, rather than a sustainable structural advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 8. Human Pharmacokinetic (PK) Data Validation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides objective, human-based evidence that the TAMP platform achieves lower systemic drug levels compared to IV delivery, supporting the safety thesis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. PK data from a Phase III trial is a high-quality data asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Competitors must run their own costly trials to generate comparable human data.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The data has been presented at major scientific symposia, showing effective communication of scientific findings.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Published, peer-supported data is difficult and expensive for rivals to overcome.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eMetric\/Data Point\u003c\/th\u003e\n\u003cth\u003eSupporting Number\/Fact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eSystemic Drug Reduction (Gemcitabine)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\u0026gt;50%\u003c\/strong\u003e reduction of floating gemcitabine in the body versus intravenous delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eTrial Phase \u0026amp; Patient Count (as of May 2, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePhase III\u003c\/strong\u003e TIGeR-PaC trial; \u003cstrong\u003e91\u003c\/strong\u003e patients randomized; \u003cstrong\u003e56\u003c\/strong\u003e events occurred\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eInvestment to Replicate (R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003eResearch and development expenses were \u003cstrong\u003e$6.0 million\u003c\/strong\u003e for the year ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eScientific Communication Venues\u003c\/td\u003e\n\u003ctd\u003eAbstracts presented at \u003cstrong\u003eSSO 2025\u003c\/strong\u003e, \u003cstrong\u003eASCO GI 2025\u003c\/strong\u003e, and \u003cstrong\u003eSociety of Interventional Oncology 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTime to Final Data Readout\u003c\/td\u003e\n\u003ctd\u003eFinal data readout expected in \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe PK analyses for the sub-study compared intra-arterial gemcitabine (IAG) via TAMP to systemic intravenous gemcitabine in a sample of participants from the TIGeR-PaC trial.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePK analyses were performed on \u003cstrong\u003e19 patients\u003c\/strong\u003e with locally advanced pancreatic cancer receiving IAG from \u003cstrong\u003esix sites\u003c\/strong\u003e as part of the TIGeR-PaC trial.\u003c\/li\u003e\n\u003cli\u003eThe current protocol for the Phase III TIGeR-PaC trial requires \u003cstrong\u003e114 randomized patients\u003c\/strong\u003e, with \u003cstrong\u003e86 events (deaths)\u003c\/strong\u003e necessary for the final analysis.\u003c\/li\u003e\n\u003cli\u003eThe Company reported R\u0026amp;D expenses of \u003cstrong\u003e$1.7 million\u003c\/strong\u003e for the first quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eA publication supporting TAMP was recognized in the \u003cstrong\u003eJournal of Vascular and Interventional Radiology Award-Winning Paper Scientific Session\u003c\/strong\u003e during the \u003cstrong\u003eSIR 2025\u003c\/strong\u003e conference.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRenovoRx, Inc. (RNXT) - VRIO Analysis: 9. Management's Dual-Track Strategy Execution\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The ability to simultaneously commercialize the device while advancing the high-value drug-device combination trial de-risks the business model. RenovoCath commercial sales began in December 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. Many companies struggle to balance commercial and R\u0026amp;D priorities effectively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. Replicating the specific leadership experience and strategic focus is not easy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Yes. CEO Shaun Bagai is actively communicating the dual focus on commercial growth and clinical progress.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. Success depends on the continued alignment and capability of the current leadership team.\u003c\/p\u003e\n\u003ch\u003eFinance: Cash Position and Revenue Milestones\u003c\/h\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds Raised\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFebruary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-to-Date Revenue (RenovoCath)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$900,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eThrough Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved Cancer Center Customers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe current cash position is believed to fund ongoing commercialization and Phase III TIGeR-PaC enrollment completion in early 2026.\u003c\/p\u003e\n\u003ch\u003eDual-Track Execution Metrics\u003c\/h\u003e\n\u003cul\u003e\n\u003cli\u003eRenovoCath Q1 2025 Revenue: Approximately \u003cstrong\u003e$200 thousand\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTIGeR-PaC Trial Enrollment Completion Target: 2025 (initial target) to early 2026 (updated target).\u003c\/li\u003e\n\u003cli\u003eRenovoCath Peak Annual U.S. Sales Opportunity Estimate: Approximately \u003cstrong\u003e$400 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516242976917,"sku":"rnxt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rnxt-vrio-analysis.png?v=1740210639","url":"https:\/\/dcf-model.com\/products\/rnxt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}